The second drug, FT-7051, is an oral, potent, and selective inhibitor of p300/CBP with activity in preclinical models of prostate cancer, including models which are resistant to the currently used AR inhibitors such as enzalutamide. This evidence concerns the gene EP300 and Familial prostate cancer.